BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
G-protein-coupled receptor binding
,
Influenza
,
Intestine
,
Holistic medicine
,
FABP1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
relapsed or refractory multiple myeloma
Summary
General Info
Curated Studies
Most Correlated Studies
Multiple myeloma U266 cells with CD9 overexpression
Explore Curated Studies Results
Literature
Most Relevant Literature
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory…
Optimization of treatment strategy for relapsed or refractory multiple myeloma].
Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multice…
Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with…
No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ